United Therapeutics Corporation (UTHR)vsZhengye Biotechnology Holding Limited Ordinary Shares (ZYBT)
UTHR
United Therapeutics Corporation
$541.60
+1.84%
HEALTHCARE · Cap: $23.74B
ZYBT
Zhengye Biotechnology Holding Limited Ordinary Shares
$0.88
+1.06%
HEALTHCARE · Cap: $41.21M
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 1970% more annual revenue ($3.18B vs $153.74M). UTHR leads profitability with a 41.9% profit margin vs -12.6%. UTHR earns a higher WallStSmart Score of 67/100 (B-).
UTHR
Strong Buy67
out of 100
Grade: B-
ZYBT
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.9%
Fair Value
$1282.02
Current Price
$541.60
$740.42 discount
Intrinsic value data unavailable for ZYBT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 45.0%
Safe zone — low bankruptcy risk
Earnings expanding 24.5% YoY
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of -6.4% — below average capital efficiency
Revenue declined 34.4%
Earnings declined 79.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.
Bull Case : ZYBT
The strongest argument for ZYBT centers on Price/Book.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio.
Bear Case : ZYBT
The primary concerns for ZYBT are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
UTHR profiles as a mature stock while ZYBT is a turnaround play — different risk/reward profiles.
UTHR is growing revenue faster at 7.4% — sustainability is the question.
UTHR generates stronger free cash flow (173M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
UTHR scores higher overall (67/100 vs 26/100), backed by strong 41.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Zhengye Biotechnology Holding Limited Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zhengye Biotechnology Holding Limited (Ticker: ZYBT) is an innovative biotechnology firm focused on the development and commercialization of advanced biopharmaceutical products. The company leverages its proprietary technologies and a diverse product pipeline to address critical medical needs, positioning itself strategically to enhance treatment outcomes across multiple therapeutic areas. With a robust commitment to research and development, ZYBT aims to drive significant growth and deliver substantial value to its investors, while maintaining a strong emphasis on quality and innovation within the dynamic biotechnology landscape.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?